Exhibit-99.1

                                 ACCESS NEWS

Contact: Company                                Contact: Investor Relations
Stephen B. Thompson                             Donald C. Weinberger
Vice President & CFO                            Wolfe Axelrod Weinberger
(214) 905-5100                                  (212) 370-4500



                    AMERICAN STOCK EXCHANGE ACCEPTS
                   ACCESS' PLAN TO REGAIN COMPLIANCE
                    WITH CONTINUED LISTING STANDARDS


DALLAS, TEXAS, July 1, 2005, ACCESS PHARMACEUTICALS, INC.
(AMEX:AKC) today announced that the American Stock Exchange
("AMEX") has accepted the Company's plan to regain compliance with the
continued listing standards by December 31, 2005.

In April 2005, the Company received notice from the AMEX Staff
indicating that the Company is below certain of AMEX's continued listing
standards, due to losses from continuing operations and/or net losses in two
of its most recent fiscal years with shareholders' equity of less than $2
million, as set forth in Section 1003(a)(i) of the AMEX "Company Guide";
due to losses from continuing operations and/or net losses in three of its
most recent fiscal years with shareholders' equity of less than $4 million,
as set forth in Section 1003(a)(ii) of the Company Guide; and due to losses
from continuing operations and/or net losses in four of its most recent fiscal
years with shareholders' equity of less than $6 million, as set forth in
Section 1003(a)(iii) of the Company Guide. The Company was afforded the
opportunity to submit a plan of compliance to AMEX and in May 2005
presented its plan to AMEX. On June 28, 2005, AMEX notified the
Company that it accepted the Company's plan of compliance and granted
the Company an extension of time

                                -More-
AccessPharmaceuticals, Inc.
Page 2

to regain compliance with the continued listing standards. The Company
will be subject to periodic review by AMEX Staff during the extension
period, during which Access is required to make progress consistent with
the plan and to regain compliance with the continued listing standards.

Access Pharmaceuticals, Inc. is an emerging pharmaceutical company
focused on developing both novel low development risk product candidates
and technologies with longer-term major product opportunities. Access
markets Aphthasol(R) and is developing products for other oral indications.
Access is also developing unique polymer platinates for use in the treatment
of cancer and has an extensive portfolio of advanced drug delivery
technologies including vitamin mediated targeted delivery, oral delivery,
and nanoparticle aggregates.

This press release contains certain statements that are forward-looking
within the meaning of Section 27a of the Securities Act of 1933, as
amended, and that involve risks and uncertainties, including but not limited
to statements made relating to our plan to regain compliance with AMEX
listing standards and improving our balance sheet and shareholders' equity.
These statements are subject to numerous risks, including but not limited
to the uncertainties associated with research and development activities,
clinical trials, our ability to raise capital, the timing of and our ability to
achieve regulatory approvals, dependence on others to market our licensed
products, collaborations, future cash flow, the timing and receipt of
licensing and milestone revenues, projected future revenue growth and our
ability to generate near term revenues, the future success of the Company's
marketed products Aphthasol(R) and products in development including
polymer platinate, and OraDisc(TM), our ability to develop products from
our platform technologies, our ability to manufacture amlexanox products
in commercial quantities, our sales projections and the sales projections of
our licensing partners, our ability to achieve licensing milestones, our
ability to repay our outstanding debt obligations and other risks detailed in
the Company's Annual Report on Form 10-K for the year ended December
31, 2004, and other reports filed by us with the Securities and Exchange
Commission.



                                 # # #